Balancing speed, science and regulatory requirements in oncology drug development

Nat Med. 2022 Nov;28(11):2234-2235. doi: 10.1038/s41591-022-01975-0.

Authors

Alexandra Snyder¹, Dinesh De Alwis², Asthika Goonewardene³, Priti S Hegde⁴

Affiliations

¹ Generate Biomedicines, Somerville, MA, USA. [email protected].
² Early Oncology Development, Merck and Co., Kenilworth, NJ, USA.
³ Truist Securities, New York, NY, USA.
⁴ Foundation Medicine, Cambridge, MA, USA. [email protected].

PMID: 36114281
DOI: 10.1038/s41591-022-01975-0

No abstract available

Publication types

Letter

MeSH terms

Drug Approval
Drug Development*
Medical Oncology*